Book a demo

Chemical intelligence powered by cypris.ai

Histrelin

(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-3-(1-benzylimidazol-4-yl)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide · also: Vantaas, Histreline, Histrelina, Vantas (TN), Histrelinum, imbzl-His(6), Pro(9)-NET-GNRH

FormulaC66H86N18O12
Mol. weight1323.528
PubChem CID25077993
InChIKeyHHXHVIJIIXKSOE-QILQGKCVSA-N
SMILESCCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CN(C=N2)CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8
15,527Patents
93Research papers
1,975Patents - last 3 years
3Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1Bayer Pharma AG1,246
2Merck Sharp & Dohme LLC631
3AbbVie Inc630
4Merck Patent GmbH616
5Bayer Intellectual Property GmbH476
6Bayer AG410
7Vertex Pharmaceuticals Inc342
8Human Genome Sciences Inc217
9Incyte Corp202
10Organon Pharma UK Ltd188

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61PTherapeutic activity (drug indications)12,813
2A61KMedicinal preparations12,352
3C07DHeterocyclic compounds7,954
4C07KPeptides2,926
5C12NMicroorganisms, enzymes1,142
6G01NInvestigating / analysing materials992
7Y02AClimate change adaptation774
8C07CAcyclic and carbocyclic compounds701
9C07BGeneral methods of organic chemistry622
10C12QMeasuring/testing involving enzymes541

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Most-cited patents

Patents ranked by forward citations reveal the foundational inventions the field continues to build on.

TitleYearAssigneeCited by
IMPLANTABLE DEVICE FOR THE DELIVERY OF HISTRELIN AND METHODS OF USE THEREOF2010Endo Pharmaceuticals Solutions Inc9
Histrelin synthesizing method2013BINHAI GL PEPTIDE CO., LTD.3
Method for synthesizing histrelin in full liquid phase2021Hunan Santai Pharmaceutical Co.,Ltd.1
Method for specifically synthesizing histrelin2017Guo Tai bio tech ltd, Hefei1
IMPLANTABLE DEVICE FOR THE DELIVERY OF HISTRELIN AND METHODS OF USE THEREOF2010Endo Pharmaceuticals Solutions Inc0

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#Research topicPapers
1Hormonal and reproductive studies1
2Pharmaceutical industry and healthcare1
3Prostate Cancer Diagnosis and Treatment1
4Prostate Cancer Treatment and Research1
5Sperm and Testicular Function1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1Amicur FarkasShaare Zedek Medical Center8
2Boris ChertinShaare Zedek Medical Center8
3C. Wayne BardinPopulation Council7
4Erica A. EugsterIndiana University – Purdue University Indianapolis7
5Irving M. SpitzBen-Gurion University of the Negev7
6K. SundaramPopulation Council7
7David R. MeldrumUniversity of California, Los Angeles6
8John K.H. LuUniversity of California, Los Angeles6
9Marcelle I. CedarsUniversity of California, Los Angeles6
10Howard L. JuddUniversity of California, Los Angeles5

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

TitleYearCited byTopic
Successful Treatment of Severe Premenstrual Syndrome by Combined Use of Gonadotropin-Releasing Hormone Agonist and Estrogen/Progestin*1991159Menstrual Health and Disorders
Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist.1987133Endometriosis Research and Treatment
The Role of Gonadotropin-Releasing Hormone in Murine Preimplantation Embryonic Development*1999114Reproductive Biology and Fertility
Clinical and Hormonal Effects of Chronic Gonadotropin Releasing Hormone Agonist Treatment in Polycystic Ovarian Disease*198796Reproductive Biology and Fertility
A Gonadotropin Releasing Hormone Analogue Prevents Cyclical Attacks of Porphyria199095Heme Oxygenase-1 and Carbon Monoxide

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular composition of Histrelin?

Histrelin has the molecular formula C66H86N18O12 and a molecular weight of 1323.528. Its IUPAC name is a complex peptide structure containing multiple amino acid residues including pyroglutamic acid, histidine, tryptophan, serine, tyrosine, leucine, arginine, and proline with specific modifications including a benzyl group on histidine and an ethyl group on the proline terminus.

What are the main patent assignees working on Histrelin technology?

The largest patent holders in the Histrelin space include Bayer Pharma AG, Merck Sharp & Dohme LLC, AbbVie Inc, and Merck Patent GmbH. Additionally, Endo Pharmaceuticals Solutions Inc holds patents on implantable delivery devices for Histrelin, and manufacturers such as BINHAI GL PEPTIDE CO., LTD., Hunan Santai Pharmaceutical Co.,Ltd., and Guo Tai bio tech ltd, Hefei hold patents on Histrelin synthesis methods.

What are the main research topics associated with Histrelin in published literature?

Academic research on Histrelin and related gonadotropin-releasing hormone agonists covers several areas including treatment of severe premenstrual syndrome, endometriosis research and treatment, reproductive biology and fertility studies, and polycystic ovarian disease. Papers in these areas have received significant citations, with one paper on premenstrual syndrome treatment receiving 159 citations.

What patent classifications are most relevant to Histrelin-related inventions?

The most common patent classification codes for Histrelin-related patents are A61P (therapeutic activities), A61K (preparations for medical, dental, or toilet purposes), C07D (heterocyclic compounds), and C07K (peptides). These reflect the compound's role as a pharmaceutical peptide with specific therapeutic applications.

What manufacturing methods have been patented for Histrelin synthesis?

Recent patents describe multiple approaches to Histrelin synthesis. These include a histrelin synthesizing method, a method for synthesizing histrelin in full liquid phase, and a method for specifically synthesizing histrelin. Patents on synthesis methods were filed between 2013 and 2021 by pharmaceutical manufacturers in China.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial